http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 13 Oct 2026 09:31:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Waters+Corp.+%28WAT%29+PT+Raised+to+%24515+at+TD+Cowen/27178871.html TD Cowen analyst Dan Brennan raised the price target on Waters Corp. (NYSE: WAT) to $515.00 (from $475.00) while maintaining a rating. http://www.streetinsider.com/Analyst+PT+Change/Waters+Corp.+%28WAT%29+PT+Raised+to+%24515+at+TD+Cowen/27178871.html Tue, 13 Oct 2026 09:31:09 -0400 WAT http://www.streetinsider.com/Corporate+News/Waters+Corporation+launches+AI+Link+software+with+Anthropic+integration/27177522.html <p>Waters Corporation (NYSE: WAT) has launched Waters AI Link, a software capability that brings Anthropic's Model Context Protocol (MCP) to its waters_connect informatics platform. The company has also joined Anthropic's Model Hardware Standard (MHS) research program, according to a company statement.</p><p>Waters AI Link connects waters_connect Software to large language models and AI agents, including Anthropic's Claude, through a natural language interface. The integration allows AI agents to create methods, run acquisitions, and process results without custom software engineering. Waters said early access is available now, with general availability planned for November for waters_connect Software customers.</p><p>The MHS program, developed by Anthropic http://www.streetinsider.com/Corporate+News/Waters+Corporation+launches+AI+Link+software+with+Anthropic+integration/27177522.html Tue, 13 Oct 2026 08:02:05 -0400 WAT http://www.streetinsider.com/Press+Releases/Waters+Launches+AI+Link%2C+Advancing+AI-Enabled+LC-MS+Workflows+from+Research+to+Release/27177338.html <div class="xn-content"> <ul type="disc"> <li>Accelerates research and development by enabling AI-augmented workflows and automated lab-in-the-loop cycles, already a new and fast-growing source of demand for Waters' instruments and consumables</li> <li>Leverages Waters' unique ability to take an AI-directed experiment from the research bench into development and into Empower™ Software, carrying its audit http://www.streetinsider.com/Press+Releases/Waters+Launches+AI+Link%2C+Advancing+AI-Enabled+LC-MS+Workflows+from+Research+to+Release/27177338.html Tue, 13 Oct 2026 08:00:00 -0400 WAT http://www.streetinsider.com/PRNewswire/Waters+Launches+AI+Link%2C+Advancing+AI-Enabled+LC-MS+Workflows+from+Research+to+Release/27177338.html <div class="xn-content"> <ul type="disc"> <li>Accelerates research and development by enabling AI-augmented workflows and automated lab-in-the-loop cycles, already a new and fast-growing source of demand for Waters' instruments and consumables</li> <li>Leverages Waters' unique ability to take an AI-directed experiment from the research bench into development and into Empower™ Software, carrying its audit http://www.streetinsider.com/PRNewswire/Waters+Launches+AI+Link%2C+Advancing+AI-Enabled+LC-MS+Workflows+from+Research+to+Release/27177338.html Tue, 13 Oct 2026 08:00:00 -0400 WAT http://www.streetinsider.com/Analyst+PT+Change/Waters+Corp.+%28WAT%29+PT+Raised+to+%24495+at+Baird/27163594.html Baird analyst Catherine Schulte raised the price target on Waters Corp. (NYSE: WAT) to $495.00 (from $456.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Waters+Corp.+%28WAT%29+PT+Raised+to+%24495+at+Baird/27163594.html Thu, 08 Oct 2026 07:24:06 -0400 WAT http://www.streetinsider.com/Analyst+PT+Change/Waters+Corp.+%28WAT%29+PT+Raised+to+%24500+at+Barclays/27156987.html Barclays analyst Luke Sergott raised the price target on Waters Corp. (NYSE: WAT) to $500.00 (from $460.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Waters+Corp.+%28WAT%29+PT+Raised+to+%24500+at+Barclays/27156987.html Wed, 07 Oct 2026 03:52:54 -0400 WAT http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++WATERS+CORP+DE++++++++++For%3A+Sep+30++Filed+by%3A+Knight+Heather/27143480.html si-local-file:///var/storage/secattach/20261002/27143480.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++WATERS+CORP+DE++++++++++For%3A+Sep+30++Filed+by%3A+Knight+Heather/27143480.html Fri, 02 Oct 2026 17:11:00 -0400 WAT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++WATERS+CORP+DE++++++++++For%3A+Sep+30++Filed+by%3A+Jiang+Wei/27143447.html si-local-file:///var/storage/secattach/20261002/27143447.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++WATERS+CORP+DE++++++++++For%3A+Sep+30++Filed+by%3A+Jiang+Wei/27143447.html Fri, 02 Oct 2026 17:09:00 -0400 WAT http://www.streetinsider.com/Press+Releases/Waters+Corporation+Schedules+Third+Quarter+2026+Earnings+Conference+Call/27132574.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.milord" idsrc="xmltag.org" >MILFORD, Mass.</location></span>, <span class="legendSpanClass"><chron>Oct. 1, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:WAT" idsrc="xmltag.org" >Waters Corporation</span> (NYSE: WAT) will hold its Q3 2026 financial results conference call on <chron>Tuesday, November 3, 2026</chron>, at <chron>8:00 a.m. Eastern Time</chron>. A live webcast of the presentation will be available on Waters' Investor Relations website at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4786897-1&amp;h=3147299637&amp;u=https%3A%2F%2Fir.waters.com%2F&amp;a=https%3A%2F%2Fir.waters.com" target="_blank" rel="nofollow">https://ir.waters.com</a>. A replay of the webcast will also be available until at least <chron>December 1, 2026</chron>, at <chron>midnight Eastern Time</chron>.</p> http://www.streetinsider.com/Press+Releases/Waters+Corporation+Schedules+Third+Quarter+2026+Earnings+Conference+Call/27132574.html Thu, 01 Oct 2026 09:00:00 -0400 WAT http://www.streetinsider.com/PRNewswire/Waters+Corporation+Schedules+Third+Quarter+2026+Earnings+Conference+Call/27132574.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.milord" idsrc="xmltag.org" >MILFORD, Mass.</location></span>, <span class="legendSpanClass"><chron>Oct. 1, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:WAT" idsrc="xmltag.org" >Waters Corporation</span> (NYSE: WAT) will hold its Q3 2026 financial results conference call on <chron>Tuesday, November 3, 2026</chron>, at <chron>8:00 a.m. Eastern Time</chron>. A live webcast of the presentation will be available on Waters' Investor Relations website at <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4786897-1&amp;h=3147299637&amp;u=https%3A%2F%2Fir.waters.com%2F&amp;a=https%3A%2F%2Fir.waters.com" target="_blank" rel="nofollow">https://ir.waters.com</a>. A replay of the webcast will also be available until at least <chron>December 1, 2026</chron>, at <chron>midnight Eastern Time</chron>.</p> http://www.streetinsider.com/PRNewswire/Waters+Corporation+Schedules+Third+Quarter+2026+Earnings+Conference+Call/27132574.html Thu, 01 Oct 2026 09:00:00 -0400 WAT http://www.streetinsider.com/Analyst+PT+Change/Waters+Corp.+%28WAT%29+PT+Raised+to+%24490+at+Guggenheim/27132289.html Guggenheim analyst Subbu Nambi raised the price target on Waters Corp. (NYSE: WAT) to $490.00 (from $440.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Waters+Corp.+%28WAT%29+PT+Raised+to+%24490+at+Guggenheim/27132289.html Thu, 01 Oct 2026 08:48:34 -0400 WAT http://www.streetinsider.com/Analyst+PT+Change/Waters+Corp.+%28WAT%29+PT+Raised+to+%24515+at+Goldman+Sachs/27082706.html Goldman Sachs analyst Matthew Sykes raised the price target on Waters Corp. (NYSE: WAT) to $515.00 (from $465.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Waters+Corp.+%28WAT%29+PT+Raised+to+%24515+at+Goldman+Sachs/27082706.html Mon, 21 Sep 2026 06:35:19 -0400 WAT http://www.streetinsider.com/Corporate+News/Waters+launches+BD+FACSDiscover+A7+Cell+Analyzer+globally/27055656.html <p>Waters Corporation (NYSE: WAT) announced the global commercial launch of the BD FACSDiscover A7 Cell Analyzer, a spectral flow cytometry instrument designed for use in academic, pharmaceutical, and contract research organization laboratories.</p> <p>The instrument incorporates BD SpectralFX Technology, which supports up to five lasers and 78 fluorescence detectors, enabling researchers to analyze more than 50 characteristics of a single cell. The A7 expands Waters' existing FACSDiscover platform, which includes the BD FACSDiscover A8 Cell Analyzer.</p> <p>The A7 includes FACSTruQ Technology, an automated calibration and quality control system that Waters says achieves a coefficient of variation of less than 10% across a palette http://www.streetinsider.com/Corporate+News/Waters+launches+BD+FACSDiscover+A7+Cell+Analyzer+globally/27055656.html Mon, 14 Sep 2026 08:00:42 -0400 WAT http://www.streetinsider.com/Press+Releases/Waters+Sets+Benchmark+for+Standardized+Spectral+Flow+Cytometry+with+Commercial+Launch+of+BD+FACSDiscover+A7+Cell+Analyzer/27055560.html <div class="xn-content"> <ul type="disc"> <li>Enables routine 50+ parameter experiments with BD SpectralFX™ Technology, accelerating breakthrough discoveries in the fight against cancer and other diseases.</li> <li>Minimizes instrument and user differences with first-of-its-kind FACSTruQ™ Technology, achieving industry-leading standardization for greater confidence in results.</li> http://www.streetinsider.com/Press+Releases/Waters+Sets+Benchmark+for+Standardized+Spectral+Flow+Cytometry+with+Commercial+Launch+of+BD+FACSDiscover+A7+Cell+Analyzer/27055560.html Mon, 14 Sep 2026 08:00:00 -0400 WAT